Eissa Sanaa, Matboli Marwa, Aboushahba Rowaida, Bekhet Miram M, Soliman Yasser
Oncology Diagnostic Unit, Medical Biochemistry and Molecular biology Department, Faculty of Medicine, Ain Shams University, P.O. box 11381, Abbassia, Cairo, Egypt.
Oncology Diagnostic Unit, Medical Biochemistry and Molecular biology Department, Faculty of Medicine, Ain Shams University, P.O. box 11381, Abbassia, Cairo, Egypt.
J Diabetes Complications. 2016 Nov-Dec;30(8):1585-1592. doi: 10.1016/j.jdiacomp.2016.07.012. Epub 2016 Jul 21.
A potential approach adopted in the current study is to design a panel based on in silico retrieval of novel miRNAs related to diabetic kidney disease and to evaluate its usefulness in disease diagnosis.
In the current study, we measured the differential expression of a 6 miRNA panel in urine pellet and exosome in an initial screening group using syber green-based PCR array. Also, we performed pathway enrichment analysis of the key target genes of these miRNAs. Finally, we selected the most significantly up-regulated miRNAs in DKD, exosomal miR-15b, miR-34a and miR-636, that were measured by real-time PCR in a larger independent set of 180 participants to evaluate their usefulness as novel urine biomarkers for diagnosis diabetic kidney disease.
PCR array analysis showed that miR-15b, miR-34a, and miR-636 were upregulated in both urine pellet and exosome of type 2DKD patients. qRT-PCR validation in the larger independent set of participants confirmed the significant up-regulation of these urinary exosomal miRs (P<0.001). Notably, a positive correlation was found between these miRs, serum creatinine and urinary protein creatinine ratio. The sensitivity of this miRs based panel in urine exosomes reached 100% in diagnosis of DKD.
We identified urinary exosomal miR-15b, miR-34a, and miR-636 as a novel diagnostic panel and a major contributor in the pathogenesis of diabetic kidney disease.
本研究采用的一种潜在方法是基于对糖尿病肾病相关新微小RNA(miRNA)的计算机检索设计一个检测组,并评估其在疾病诊断中的效用。
在本研究中,我们使用基于荧光定量PCR的PCR阵列,在一个初始筛查组中测量了一个包含6种miRNA的检测组在尿沉渣和外泌体中的差异表达。此外,我们对这些miRNA的关键靶基因进行了通路富集分析。最后,我们选择了在糖尿病肾病(DKD)中上调最显著的miRNA,即外泌体miR-15b、miR-34a和miR-636,并在一个由180名参与者组成的更大独立队列中通过实时PCR对其进行测量,以评估它们作为糖尿病肾病诊断新型尿液生物标志物的效用。
PCR阵列分析显示,miR-15b、miR-34a和miR-636在2型糖尿病肾病患者的尿沉渣和外泌体中均上调。在更大的独立参与者队列中的qRT-PCR验证证实了这些尿外泌体miRNA的显著上调(P<0.001)。值得注意的是,这些miRNA与血清肌酐和尿蛋白肌酐比值之间存在正相关。基于这些miRNA的尿外泌体检测组在糖尿病肾病诊断中的敏感性达到100%。
我们确定尿外泌体miR-15b、miR-34a和miR-636是一种新型诊断检测组,也是糖尿病肾病发病机制的主要促成因素。